Colorectal cancer (CRC) ranks among the most common cancers worldwide. Surgical removal remains the best strategy for treatment of resectable tumors. An important part of caring for patients after surgery is monitoring for early detection of a possible relapse of the disease. Efforts are being made to improve the sensitivity and specificity of routinely used carcinoembryonic antigen (CEA) with the use of additional biomarkers such as microRNAs. The aim of our study was to evaluate the prognostic potential of microRNAs and their use as markers of disease recurrence. The quantitative estimation of CEA, CA19-9, and 22 selected microRNAs (TaqMan Advanced miRNA Assays) was performed in 85 paired (preoperative and postoperative) blood plasma samples of CRC patients and in samples taken during the follow-up period. We have revealed a statistically significant decrease in plasma levels for miR-20a, miR-23a, miR-210, and miR-223a (p = 0.0093, p = 0.0013, p = 0.0392, and p = 0.0214, respectively) after surgical removal of the tumor tissue. A statistically significant relation to prognosis (overall survival; OS) was recorded for preoperative plasma levels of miR-20a, miR-21, and miR-23a (p = 0.0236, p = 0.0316, and p =0.0271, respectively) in a subgroup of patients who underwent palliative surgery. The best discrimination between patients with favorable and unfavorable outcomes was achieved by a combination of CEA, CA19-9 with miR-21, miR-20a, and miR-23a (p < 0.0001). The use of these microRNAs for early disease recurrence detection was affected by a low specificity in comparison with CEA and CA19-9. CEA and CA19-9 had high specificity but low sensitivity. Our results show the benefit of combining currently used standard biomarkers and microRNAs for precise prognosis estimation.

Department of Biology Faculty of Medicine in Pilsen Charles University alej Svobody 76 32300 Pilsen Czech Republic

Department of Histology and Embryology Faculty of Medicine in Pilsen Charles University Karlovarska 48 30166 Pilsen Czech Republic

Department of Medical Chemistry and Biochemistry Faculty of Medicine in Pilsen Charles University Karlovarska 48 30166 Pilsen Czech Republic

Laboratory of Immunoanalysis University Hospital in Pilsen E Benese 13 30599 Pilsen Czech Republic

Zobrazit více v PubMed

Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394–424. doi: 10.3322/caac.21492. PubMed DOI

Hagan S., Orr M.C.M., Doyle B. Targeted therapies in colorectal cancer-an integrative view by PPPM. EPMA J. 2013;4:3. doi: 10.1186/1878-5085-4-3. PubMed DOI PMC

Kalyan A., Kircher S., Shah H., Mulcahy M., Benson A. Updates on immunotherapy for colorectal cancer. J. Gastrointest. Oncol. 2018;9:160–169. doi: 10.21037/jgo.2018.01.17. PubMed DOI PMC

Wille-Jørgensen P., Syk I., Smedh K., Laurberg S., Nielsen D.T., Petersen S.H., Renehan A.G., Horváth-Puhó E., Påhlman L., Sørensen H.T., et al. Effect of more vs. less frequent follow-up testing on overall and colorectal cancer-specific mortality in patients with stage II or III colorectal cancer: The colofol randomized clinical trial. Jama. 2018;319:2095–2103. doi: 10.1001/jama.2018.5623. PubMed DOI PMC

Duffy M.J., van Dalen A., Haglund C., Hansson L., Holinski-Feder E., Klapdor R., Lamerz R., Peltomaki P., Sturgeon C., Topolcan O. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur. J. Cancer. 2007;43:1348–1360. doi: 10.1016/j.ejca.2007.03.021. PubMed DOI

Locker G.Y., Hamilton S., Harris J., Jessup J.M., Kemeny N., Macdonald J.S., Somerfield M.R., Hayes D.F., Bast R.C. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J. Clin. Oncol. 2006;24:5313–5327. doi: 10.1200/JCO.2006.08.2644. PubMed DOI

Tan E., Gouvas N., Nicholls R.J., Ziprin P., Xynos E., Tekkis P.P. Diagnostic precision of carcinoembryonic antigen in the detection of recurrence of colorectal cancer. Surg. Oncol. 2009;18:15–24. doi: 10.1016/j.suronc.2008.05.008. PubMed DOI

Park I.J., Choi G.-S., Lim K.H., Kang B.M., Jun S.H. Serum carcinoembryonic antigen monitoring after curative resection for colorectal cancer: Clinical significance of the preoperative level. Ann. Surg. Oncol. 2009;16:3087–3093. doi: 10.1245/s10434-009-0625-z. PubMed DOI

Kawamura Y.J., Tokumitsu A., Mizokami K., Sasaki J., Tsujinaka S., Konishi F. First alert for recurrence during follow-up after potentially curative resection for colorectal carcinoma: CA 19-9 should be included in surveillance programs. Clin. Colorectal Cancer. 2010;9:48–51. doi: 10.3816/CCC.2010.n.006. PubMed DOI

Pan C., Yan X., Li H., Huang L., Yin M., Yang Y., Gao R., Hong L., Ma Y., Shi C., et al. Systematic literature review and clinical validation of circulating microRNAs as diagnostic biomarkers for colorectal cancer. Oncotarget. 2017;8:68317–68328. doi: 10.18632/oncotarget.19344. PubMed DOI PMC

Kozomara A., Birgaoanu M., Griffiths-Jones S. miRBase: From microRNA sequences to function. Nucleic Acids Res. 2019;47:D155–D162. doi: 10.1093/nar/gky1141. PubMed DOI PMC

Catalanotto C., Cogoni C., Zardo G. MicroRNA in control of gene expression: An overview of nuclear functions. Int. J. Mol. Sci. 2016;17:1712. doi: 10.3390/ijms17101712. PubMed DOI PMC

Aghdam S.G., Ebrazeh M., Hemmatzadeh M., Seyfizadeh N., Shabgah A.G., Azizi G., Ebrahimi N., Babaie F., Mohammadi H. The role of microRNAs in prostate cancer migration, invasion, and metastasis. J. Cell. Physiol. 2019;234:9927–9942. doi: 10.1002/jcp.27948. PubMed DOI

Smid D., Kulda V., Srbecka K., Kubackova D., Dolezal J., Daum O., Kucera R., Topolcan O., Treska V., Skalicky T., et al. Tissue microRNAs as predictive markers for gastric cancer patients undergoing palliative chemotherapy. Int. J. Oncol. 2016;48:2693–2703. doi: 10.3892/ijo.2016.3484. PubMed DOI

Pratap P., Raza S.T., Abbas S., Mahdi F. MicroRNA-associated carcinogenesis in lung carcinoma. J. Cancer Res. Ther. 2018;14:249–254. PubMed

Guo Y., Bao Y., Yang W. Regulatory miRNAs in colorectal carcinogenesis and metastasis. Int. J. Mol. Sci. 2017;18:890. doi: 10.3390/ijms18040890. PubMed DOI PMC

Kulda V., Pesta M., Topolcan O., Liska V., Treska V., Sutnar A., Rupert K., Ludvikova M., Babuska V., Holubec L., et al. Relevance of miR-21 and miR-143 expression in tissue samples of colorectal carcinoma and its liver metastases. Cancer Genet. Cytogenet. 2010;200:154–160. doi: 10.1016/j.cancergencyto.2010.04.015. PubMed DOI

Du B., Wu D., Yang X., Wang T., Shi X., Lv Y., Zhou Z., Liu Q., Zhang W. The expression and significance of microRNA in different stages of colorectal cancer. Medicine. 2018;97:e9635. doi: 10.1097/MD.0000000000009635. PubMed DOI PMC

Vychytilova-Faltejskova P., Radova L., Sachlova M., Kosarova Z., Slaba K., Fabian P., Grolich T., Prochazka V., Kala Z., Svoboda M., et al. Serum-based microRNA signatures in early diagnosis and prognosis prediction of colon cancer. Carcinogenesis. 2016;37:941–950. doi: 10.1093/carcin/bgw078. PubMed DOI

Fang Z., Tang J., Bai Y., Lin H., You H., Jin H., Lin L., You P., Li J., Dai Z., et al. Plasma levels of microRNA-24, microRNA-320a, and microRNA-423-5p are potential biomarkers for colorectal carcinoma. J. Exp. Clin. Cancer Res. 2015;34:86. doi: 10.1186/s13046-015-0198-6. PubMed DOI PMC

Maierthaler M., Benner A., Hoffmeister M., Surowy H., Jansen L., Knebel P., Chang-Claude J., Brenner H., Burwinkel B. Plasma miR-122 and miR-200 family are prognostic markers in colorectal cancer. Int. J. Cancer. 2017;140:176–187. doi: 10.1002/ijc.30433. PubMed DOI

Ulivi P., Canale M., Passardi A., Marisi G., Valgiusti M., Frassineti G.L., Calistri D., Amadori D., Scarpi E. Circulating plasma levels of miR-20b, miR-29b and miR-155 as predictors of bevacizumab efficacy in patients with metastatic colorectal cancer. Int. J. Mol. Sci. 2018;19:307. doi: 10.3390/ijms19010307. PubMed DOI PMC

Nikolaou S., Qiu S., Fiorentino F., Rasheed S., Tekkis P., Kontovounisios C. Systematic review of blood diagnostic markers in colorectal cancer. Tech. Coloproctol. 2018;22:481–498. doi: 10.1007/s10151-018-1820-3. PubMed DOI PMC

Saito G., Sadahiro S., Kamata H., Miyakita H., Okada K., Tanaka A., Suzuki T. Monitoring of serum carcinoembryonic antigen levels after curative resection of colon cancer: Cutoff values determined according to preoperative levels enhance the diagnostic accuracy for recurrence. Oncology. 2017;92:276–282. doi: 10.1159/000456075. PubMed DOI PMC

Wang J., Wang X., Yu F., Chen J., Zhao S., Zhang D., Yu Y., Liu X., Tang H., Peng Z. Combined detection of preoperative serum CEA, CA19-9 and CA242 improve prognostic prediction of surgically treated colorectal cancer patients. Int. J. Clin. Exp. Pathol. 2015;8:14853–14863. PubMed PMC

Yang S.-H., Jiang J.-K., Chang S.-C., Juang C.-J., Lin J.-K. Clinical significance of CA19-9 in the follow-up of colorectal cancer patients with elevated preoperative serum CA19-9. Hepatogastroenterology. 2013;60:1021–1027. PubMed

Yong F.L., Law C.W., Wang C.W. Potentiality of a triple microRNA classifier: miR-193a-3p, miR-23a and miR-338-5p for early detection of colorectal cancer. BMC Cancer. 2013;13:280. doi: 10.1186/1471-2407-13-280. PubMed DOI PMC

Deng Y.H., Deng Z.H., Hao H., Wu X.L., Gao H., Tang S.H., Tang H. MicroRNA-23a promotes colorectal cancer cell survival by targeting PDK4. Exp. Cell Res. 2018;373:171–179. doi: 10.1016/j.yexcr.2018.10.010. PubMed DOI

Jin F., Yang R., Wei Y., Wang D., Zhu Y., Wang X., Lu Y., Wang Y., Zen K., Li L. HIF-1α-induced miR-23a∼27a∼24 cluster promotes colorectal cancer progression via reprogramming metabolism. Cancer Lett. 2019;440–441:211–222. doi: 10.1016/j.canlet.2018.10.025. PubMed DOI

Wang N., Tan H.-Y., Feng Y.-G., Zhang C., Chen F., Feng Y. microRNA-23a in human cancer: Its roles, mechanisms and therapeutic relevance. Cancers. 2018;11:7. doi: 10.3390/cancers11010007. PubMed DOI PMC

Earle J.S.L., Luthra R., Romans A., Abraham R., Ensor J., Yao H., Hamilton S.R. Association of microRNA expression with microsatellite instability status in colorectal adenocarcinoma. J. Mol. Diagn. 2010;12:433–440. doi: 10.2353/jmoldx.2010.090154. PubMed DOI PMC

Zekri A.-R.N., Youssef A.S.E.-D., Lotfy M.M., Gabr R., Ahmed O.S., Nassar A., Hussein N., Omran D., Medhat E., Eid S., et al. Circulating serum miRNAs as diagnostic markers for colorectal cancer. PLoS ONE. 2016;11:e0154130. doi: 10.1371/journal.pone.0154130. PubMed DOI PMC

Ju H., Tan J.-Y., Cao B., Song M.-Q., Tian Z.-B. Effects of miR-223 on colorectal cancer cell proliferation and apoptosis through regulating FoxO3a/BIM. Eur. Rev. Med. Pharmacol. Sci. 2018;22:3771–3778. PubMed

Li Z., Yang Y., Du L., Dong Z., Wang L., Zhang X., Zhou X., Zheng G., Qu A., Wang C. Overexpression of miR-223 correlates with tumor metastasis and poor prognosis in patients with colorectal cancer. Med. Oncol. 2014;31:256. doi: 10.1007/s12032-014-0256-5. PubMed DOI

Zhang H., Li P., Ju H., Pesta M., Kulda V., Jin W., Cai M., Liu C., Wu H., Xu J., et al. Diagnostic and prognostic value of microRNA-21 in colorectal cancer: An original study and individual participant data meta-analysis. Cancer Epidemiol. Biomark. Prev. 2014;23:2783–2792. doi: 10.1158/1055-9965.EPI-14-0598. PubMed DOI

Guraya S. Prognostic significance of circulating microRNA-21 expression in esophageal, pancreatic and colorectal cancers; a systematic review and meta-analysis. Int. J. Surg. 2018;60:41–47. doi: 10.1016/j.ijsu.2018.10.030. PubMed DOI

Yang Q., Wang S., Huang J., Xia C., Jin H., Fan Y. Serum miR-20a and miR-486 are potential biomarkers for discriminating colorectal neoplasia: A pilot study. J. Cancer Res. Ther. 2018;14:1572–1577. PubMed

Yamada A., Horimatsu T., Okugawa Y., Nishida N., Honjo H., Ida H., Kou T., Kusaka T., Sasaki Y., Yagi M., et al. Serum miR-21, miR-29a, and miR-125b are promising biomarkers for the early detection of colorectal neoplasia. Clin. Cancer Res. 2015;21:4234–4242. doi: 10.1158/1078-0432.CCR-14-2793. PubMed DOI PMC

Li X., Wei Y., Wang Z. microRNA-21 and hypertension. Hypertens. Res. 2018;41:649–661. doi: 10.1038/s41440-018-0071-z. PubMed DOI

Tay Y., Rinn J., Pandolfi P.P. The multilayered complexity of ceRNA crosstalk and competition. Nature. 2014;505:344–352. doi: 10.1038/nature12986. PubMed DOI PMC

Sobin L., Gospodarowicz M., Wittekind C. TNM Classification of Malignant Tumours. 7th ed. Wiley-Blackwell; New York, NY, USA: 2009.

Schwartz L.H., Litière S., de Vries E., Ford R., Gwyther S., Mandrekar S., Shankar L., Bogaerts J., Chen A., Dancey J., et al. RECIST 1.1-Update and clarification: From the RECIST committee. Eur. J. Cancer. 2016;62:132–137. doi: 10.1016/j.ejca.2016.03.081. PubMed DOI PMC

Faltejskova P., Bocanek O., Sachlova M., Svoboda M., Kiss I., Vyzula R., Slaby O. Circulating miR-17-3p, miR-29a, miR-92a and miR-135b in serum: Evidence against their usage as biomarkers in colorectal cancer. Cancer Biomark. Sect. Dis. Markers. 2012;12:199–204. doi: 10.3233/CBM-130308. PubMed DOI

Li J., Liu Y., Wang C., Deng T., Liang H., Wang Y., Huang D., Fan Q., Wang X., Ning T., et al. Serum miRNA expression profile as a prognostic biomarker of stage II/III colorectal adenocarcinoma. Sci. Rep. 2015;5:12921. doi: 10.1038/srep12921. PubMed DOI PMC

Brunet Vega A., Pericay C., Moya I., Ferrer A., Dotor E., Pisa A., Casalots À., Serra-Aracil X., Oliva J.-C., Ruiz A., et al. microRNA expression profile in stage III colorectal cancer: Circulating miR-18a and miR-29a as promising biomarkers. Oncol. Rep. 2013;30:320–326. doi: 10.3892/or.2013.2475. PubMed DOI

Ristau J., Staffa J., Schrotz-King P., Gigic B., Makar K.W., Hoffmeister M., Brenner H., Ulrich A., Schneider M., Ulrich C.M., et al. Suitability of circulating miRNAs as potential prognostic markers in colorectal cancer. Cancer Epidemiol. Biomark. Prev. 2014;23:2632–2637. doi: 10.1158/1055-9965.EPI-14-0556. PubMed DOI PMC

Pellatt D.F., Stevens J.R., Wolff R.K., Mullany L.E., Herrick J.S., Samowitz W., Slattery M.L. Expression profiles of miRNA subsets distinguish human colorectal carcinoma and normal colonic mucosa. Clin. Transl. Gastroenterol. 2016;7:e152. doi: 10.1038/ctg.2016.11. PubMed DOI PMC

Yin J., Bai Z., Song J., Yang Y., Wang J., Han W., Zhang J., Meng H., Ma X., Yang Y., et al. Differential expression of serum miR-126, miR-141 and miR-21 as novel biomarkers for early detection of liver metastasis in colorectal cancer. Chin. J. Cancer Res. 2014;26:95–103. PubMed PMC

Toiyama Y., Takahashi M., Hur K., Nagasaka T., Tanaka K., Inoue Y., Kusunoki M., Boland C.R., Goel A. Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J. Natl. Cancer Inst. 2013;105:849–859. doi: 10.1093/jnci/djt101. PubMed DOI PMC

Ogata-Kawata H., Izumiya M., Kurioka D., Honma Y., Yamada Y., Furuta K., Gunji T., Ohta H., Okamoto H., Sonoda H., et al. Circulating exosomal microRNAs as biomarkers of colon cancer. PLoS ONE. 2014;9:e92921. doi: 10.1371/journal.pone.0092921. PubMed DOI PMC

Zheng G., Du L., Yang X., Zhang X., Wang L., Yang Y., Li J., Wang C. Serum microRNA panel as biomarkers for early diagnosis of colorectal adenocarcinoma. Br. J. Cancer. 2014;111:1985–1992. doi: 10.1038/bjc.2014.489. PubMed DOI PMC

Sun Y., Liu Y., Cogdell D., Calin G.A., Sun B., Kopetz S., Hamilton S.R., Zhang W. Examining plasma microRNA markers for colorectal cancer at different stages. Oncotarget. 2016;7:11434–11449. doi: 10.18632/oncotarget.7196. PubMed DOI PMC

Yang I.-P., Tsai H.-L., Miao Z.-F., Huang C.-W., Kuo C.-H., Wu J.-Y., Wang W.-M., Juo S.-H.H., Wang J.-Y. Development of a deregulating microRNA panel for the detection of early relapse in postoperative colorectal cancer patients. J. Transl. Med. 2016;14:108. doi: 10.1186/s12967-016-0856-2. PubMed DOI PMC

Hongliang C., Shaojun H., Aihua L., Hua J. Correlation between expression of miR-155 in colon cancer and serum carcinoembryonic antigen level and its contribution to recurrence and metastasis forecast. Saudi Med. J. 2014;35:547–553. PubMed

Chen J., Wang W., Zhang Y., Chen Y., Hu T. Predicting distant metastasis and chemoresistance using plasma miRNAs. Med. Oncol. 2014;31:799. doi: 10.1007/s12032-013-0799-x. PubMed DOI

Yuan D., Li K., Zhu K., Yan R., Dang C. Plasma miR-183 predicts recurrence and prognosis in patients with colorectal cancer. Cancer Biol. Ther. 2015;16:268–275. doi: 10.1080/15384047.2014.1002327. PubMed DOI PMC

Nonaka R., Nishimura J., Kagawa Y., Osawa H., Hasegawa J., Murata K., Okamura S., Ota H., Uemura M., Hata T., et al. Circulating miR-199a-3p as a novel serum biomarker for colorectal cancer. Oncol. Rep. 2014;32:2354–2358. doi: 10.3892/or.2014.3515. PubMed DOI

Liu M., Zhi Q., Wang W., Zhang Q., Fang T., Ma Q. Up-regulation of miR-592 correlates with tumor progression and poor prognosis in patients with colorectal cancer. Biomed. Pharmacother. 2015;69:214–220. doi: 10.1016/j.biopha.2014.12.001. PubMed DOI

Kroh E.M., Parkin R.K., Mitchell P.S., Tewari M. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR) Methods. 2010;50:298–301. doi: 10.1016/j.ymeth.2010.01.032. PubMed DOI PMC

Hellemans J., Mortier G., De Paepe A., Speleman F., Vandesompele J. qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol. 2007;8:R19. doi: 10.1186/gb-2007-8-2-r19. PubMed DOI PMC

Schwarzenbach H., da Silva A.M., Calin G., Pantel K. Data normalization strategies for MicroRNA quantification. Clin. Chem. 2015;61:1333–1342. doi: 10.1373/clinchem.2015.239459. PubMed DOI PMC

The impact of obesity, age, and gender on plasmatic levels of selected glycoprotein biomarkers and miRNA-499 in OSA patients

The Level of Preoperative Plasma KRAS Mutations and CEA Predict Survival of Patients Undergoing Surgery for Colorectal Cancer Liver Metastases